Zogenix Inc ZGNX:NASDAQ

RT Quote | NASDAQ | USD
Last | 06/22/21 EDT
17.64quote price arrow down-0.46 (-2.54%)
Volume
1,082,944
52 week range
16.73 - 32.42

...

Loading . . .
  • Open18.02
  • Day High18.12
  • Day Low17.48
  • Prev Close17.64
  • 52 Week High32.42
  • 52 Week High Date06/26/20
  • 52 Week Low16.73
  • 52 Week Low Date05/06/21

Key Stats

  • Market Cap984.49M
  • Shares Out55.81M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta1.40
  • YTD % Change-11.76

KEY STATS

  • Open18.02
  • Day High18.12
  • Day Low17.48
  • Prev Close17.64
  • 52 Week High32.42
  • 52 Week High Date06/26/20
  • 52 Week Low16.73
  • 52 Week Low Date05/06/21
  • Market Cap984.49M
  • Shares Out55.81M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta1.40
  • YTD % Change-11.76

RATIOS/PROFITABILITY

  • EPS (TTM)-4.30
  • P/E (TTM)-4.10
  • Fwd P/E (NTM)-5.86
  • EBITDA (MRQ)-235.939M
  • ROE (MRQ)-61.99%
  • Revenue (MRQ)26.08M
  • Gross Margin (MRQ)91.37%
  • Net Margin (MRQ)-917.30%
  • Debt To Equity (MRQ)47.14%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Zogenix Inc

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United...
Cam Garner
Non-Executive Chairman
Stephen Farr Ph.D.
President
Michael Smith
Chief Financial Officer
Shawnte Mitchell
Executive Vice President
Gail Farfel Ph.D.
Executive Vice President
Address
5959 Horton St Ste 500
Emeryville, CA
94608-2120
United States

Top Peers

SYMBOLLASTCHG%CHG
OCUL
Ocular Therapeutix Inc
13.79-0.14-1.00%
OMER
Omeros Corp
15.46+0.14+0.91%
AERI
Aerie Pharmaceuticals Inc
17.71-0.09-0.51%
CDXC
Chromadex Corp
8.88-0.11-1.22%
TVTX
Travere Therapeutics Inc
14.90-0.11-0.73%